The Radicle Way

“As bio-pharmaceutical industry leaders, the MD FARMA team is proud to partner with Radicle Science in the mission to develop practical data, and further the credibility of high quality cannabinoid therapy as we expedite its entry into the mainstream of evidence-based healthcare to benefit the millions of patients seeking natural therapeutics.”

“The Radicle ACES study aims to answer lingering questions as to who should take cannabidiol, how much and for what conditions, as well as differing dosage patterns. CBD is much more subtle in its effects and quite benign compared to THC. Patients are unclear on what product to choose and healthcare providers don’t yet have the data to counsel on proper dosage.”

"At Maven Hemp, we believe in the importance of having access to verified data that supports the ways our company makes a positive impact. Participating in the Radicle ACES study allows us to align with Radicle, a B-corp that shares our values, while building trust and confidence as we work to distribute our products to doctors and patients across Latin America and beyond. We're in the process of B-corp certification, and are making progress towards our impact goals every day. We're proud to align with mission-driven partners, including Radicle Science and the other 12 brands in the Radicle ACES study."

“The Radicle ACES study is groundbreaking, as it will move the industry from anecdotal hearsay regarding CBD efficacy to concrete scientific data. While most clinical studies focus on a very narrow aspect of CBD, the ACES study will utilize a large sample group and cover a wide range of products to investigate the effectiveness of specific products for specific purposes.”

"Radicle ACES is a groundbreaking new approach to conducting clinical trials. Taking advantage of the newly established infrastructure of connectivity, and technology that allows for remote patient monitoring and data collection, Radicle ACES will complete rigorous clinical research at an unprecedented scale and speed. This approach also makes clinical trials accessible to larger and more representative populations. The results of the Radicle ACES research program will help answer critical questions about the efficacy and safety of specific CBD products for targeted health-related effects."

“As a brand committed to supporting the well-being of all, we’re thrilled to partner with Radicle Science on this first-of-it’s-kind Real World Evidence study. We hope the [Radicle ACES] research will further champion and normalize the use of CBD as an evidenced-based ingredient in support of holistic well-being.”

"The value and credibility that the Radicle ACES study will bring to the commercial CBD space is rooted in the trusted, scientifically-evaluated first-party data and a level of transparency that consumers would traditionally demand and have access to before purchasing a wellness product in a parallel category. We know that not all CBD is created equal and, given the research in this category has historically been focused specifically on cannabinoids in isolation, not as part of a fully formulated product commercially available to consumers, we believe the findings of this study will bring a lot of validity to our products and other leading products in the space."

"Marketing departments do a good job at selling comfort, security, and effectiveness. Let's be honest, when was the last time that you saw a label on a supplement product that said this product DOESN'T work? Rather than simply taking the brand's "word for it", Radicle provides an evidence-based platform that empowers consumers to make the best choice for themselves and the condition they are managing."

"The collaboration between Radicle Science, academic medicine, and therapeutically focused cannabis brands makes the Radicle ACES trial particularly exciting. We are thrilled to be part of a rigorous investigation into how Trokie and other clinically relevant CBD products can improve the lives of patients, and also hopefully expand the avenues for more clinical cannabinoid research."